CO6290645A2 - Compuesto para el tratamiento de la hepatitis c - Google Patents

Compuesto para el tratamiento de la hepatitis c

Info

Publication number
CO6290645A2
CO6290645A2 CO10134256A CO10134256A CO6290645A2 CO 6290645 A2 CO6290645 A2 CO 6290645A2 CO 10134256 A CO10134256 A CO 10134256A CO 10134256 A CO10134256 A CO 10134256A CO 6290645 A2 CO6290645 A2 CO 6290645A2
Authority
CO
Colombia
Prior art keywords
treatment
hepatitis
composite
compounds
hcv
Prior art date
Application number
CO10134256A
Other languages
English (en)
Inventor
Scott W Martin
Carl P Bergstrom
Min Ding
Xiaofan Zheng
Robert G Gentles
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40786514&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6290645(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CO6290645A2 publication Critical patent/CO6290645A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Abstract

La invención comprende compuestos de fórmula I así como composiciones y procedimientos de uso de los compuestos. Los compuestos tienen actividad contra el virus de la hepatitis C (VHC) y son útiles en el tratamiento de aquellos infectados por VHC.
CO10134256A 2008-05-06 2010-10-28 Compuesto para el tratamiento de la hepatitis c CO6290645A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5074308P 2008-05-06 2008-05-06

Publications (1)

Publication Number Publication Date
CO6290645A2 true CO6290645A2 (es) 2011-06-20

Family

ID=40786514

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10134256A CO6290645A2 (es) 2008-05-06 2010-10-28 Compuesto para el tratamiento de la hepatitis c

Country Status (19)

Country Link
US (1) US8133884B2 (es)
EP (1) EP2280975B1 (es)
JP (1) JP2011520810A (es)
KR (1) KR20110015588A (es)
CN (1) CN102083834A (es)
AR (1) AR071684A1 (es)
AU (1) AU2009244409A1 (es)
BR (1) BRPI0915130A2 (es)
CA (1) CA2723683A1 (es)
CL (1) CL2009001089A1 (es)
CO (1) CO6290645A2 (es)
EA (1) EA201001748A1 (es)
IL (1) IL208753A0 (es)
MX (1) MX2010011921A (es)
NZ (1) NZ588556A (es)
PE (1) PE20091879A1 (es)
TW (1) TW200951135A (es)
WO (1) WO2009137454A1 (es)
ZA (1) ZA201007649B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
WO2009120650A1 (en) 2008-03-27 2009-10-01 Bristol-Myers Squibb Company Aromatic heterocyclic fused indolobenzadiazepine hcv ns5b inhibitors
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
CN103649079B (zh) 2010-12-22 2016-11-16 Abbvie公司 丙型肝炎抑制剂及其用途
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
US9073943B2 (en) 2012-02-10 2015-07-07 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
EA025391B1 (ru) * 2012-07-18 2016-12-30 Бристол-Майерс Сквибб Холдингс Айеленд НОВЫЕ СПОСОБЫ И ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ ДЛЯ ПОЛУЧЕНИЯ (4bS,5aR)-12-ЦИКЛОГЕКСИЛ-N-(N,N-ДИМЕТИЛСУЛЬФАМОИЛ)-3-МЕТОКСИ-5a-((1R,5S)-3-МЕТИЛ-3,8-ДИАЗАБИЦИКЛО[3.2.1]ОКТАН-8-КАРБОНИЛ)-4b,5,5a,6-ТЕТРАГИДРОБЕНЗО[3,4]ЦИКЛОПРОПА[5,6]АЗЕПИНО[1,2-a]ИНДОЛ-9-КАРБОКСАМИДА

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1719773E (pt) 2004-02-24 2009-06-03 Japan Tobacco Inc Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
MX2007004979A (es) 2004-10-26 2007-06-14 Angeletti P Ist Richerche Bio Derivados de indol tetraciclicos como agentes antiviricos.
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
EP2029606B1 (en) 2006-05-25 2010-05-26 Brystol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2007140200A2 (en) 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7541351B2 (en) 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538102B2 (en) 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7547690B2 (en) 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7521444B2 (en) 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7541353B2 (en) 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538103B2 (en) 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US20090018163A1 (en) 2007-07-11 2009-01-15 Bristol-Myers Squibb Company Substituted Heterocyclic Ethers and Their Use in CNS Disorders
US7642251B2 (en) 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7652004B2 (en) 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8129367B2 (en) 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8124601B2 (en) 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C

Also Published As

Publication number Publication date
EP2280975A1 (en) 2011-02-09
PE20091879A1 (es) 2009-12-19
MX2010011921A (es) 2010-11-30
AU2009244409A1 (en) 2009-11-12
WO2009137454A1 (en) 2009-11-12
EA201001748A1 (ru) 2011-06-30
NZ588556A (en) 2012-06-29
IL208753A0 (en) 2010-12-30
EP2280975B1 (en) 2014-01-01
CA2723683A1 (en) 2009-11-12
ZA201007649B (en) 2012-04-25
BRPI0915130A2 (pt) 2019-09-24
US20090280083A1 (en) 2009-11-12
TW200951135A (en) 2009-12-16
KR20110015588A (ko) 2011-02-16
CN102083834A (zh) 2011-06-01
JP2011520810A (ja) 2011-07-21
AR071684A1 (es) 2010-07-07
CL2009001089A1 (es) 2011-04-29
US8133884B2 (en) 2012-03-13

Similar Documents

Publication Publication Date Title
DE602007006796D1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b-hemmer
CY1111423T1 (el) Αναστολεις ns5b hcv
DK2209789T3 (da) Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere
CO6290645A2 (es) Compuesto para el tratamiento de la hepatitis c
CO6361922A2 (es) Inhibidores del virus de la hepatitis c
CO6430431A2 (es) Inhibidores del virus de la hepatitis c
CL2012002489A1 (es) Compuestos derivados de sililo nafto-imidazol; composición farmacéutica; y su uso para prevenir o tratar una infección por el virus de la hepatitis c.
EA200901241A1 (ru) Соединения для лечения гепатита с
ECSP13013019A (es) Derivados de nucleósidos 2'- sustituidos y métodos de uso de los mismos para el tratamiento de enfermedades virales
EA201100390A1 (ru) Соединения для лечения гепатита с
CR20110605A (es) Compuestos heterocíclicos antivirales
ATE522532T1 (de) Verbindungen zur behandlung von hepatitis c
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
ECSP10010210A (es) Compuestos nucleósidos antivirales
ATE551343T1 (de) Tetracyclische verbindungen zur behandlung von hepatitis c
CL2013003171A1 (es) Compuesto macrociclico derivado de prolina inhibidor de la proteasa serina ns3; su composicion farmaceutica; y su uso en el tratamiento de una infeccion viral, en particular una infeccion causada por el virus de la hepatitis c (vhc).
ATE494291T1 (de) Verbindungen zur behandlung von hepatitis c
UY32721A (es) Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
ATE505473T1 (de) Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c
UY32720A (es) Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados
SV2007002309A (es) Compuestos 5-nitro-nucleosidos para tratar infecciones virales
EA201270798A1 (ru) Соединения для лечения гепатита с
MX2010010061A (es) Compuestos para el tratamiento de hepatitis c.
ATE531373T1 (de) Aromatische heterocyclische kondensierte indolobenzadiazepin-hcv-ns5b-inhibitoren

Legal Events

Date Code Title Description
FC Application refused